Aortic Stent Grafts was Artivion’s largest product and service line in fiscal 2025, bringing in $159.37M of $441.33M (36%).
| Product and Service | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aortic Stent Grafts | $92.75M | $107.47M | $123.08M | $159.37M | ||||||||||||
| Preservation Services | $83.44M | $92.82M | $98.31M | $95.51M | ||||||||||||
| Surgical Sealants | $65.38M | $68.02M | $73.90M | $76.60M | ||||||||||||
| Bioglue | — | — | — | — | ||||||||||||
| Aortic Stents & Stent Grafts | — | — | — | — | ||||||||||||
| On-X | $63.90M | $74.53M | $83.98M | $101.74M | ||||||||||||
| Bioglue & Biofoam | — | — | — | — | ||||||||||||
| Vascular Tissues | — | — | — | — | ||||||||||||
| Vascular Tissue | — | — | — | — | ||||||||||||
| Cardiac Tissues | — | — | — | — | ||||||||||||
| Cardiac Tissue | — | — | — | — | ||||||||||||
| Other | $8.32M | $11.17M | $9.27M | $8.11M | ||||||||||||
| Revascularization Technologies | — | — | — | — | ||||||||||||
| Hemostase | — | — | — | — | ||||||||||||
| Hero Graft | — | — | — | — | ||||||||||||
| Perclot | — | — | — | — | ||||||||||||
| Photofix | — | — | — | — | ||||||||||||
| Procol | — | — | — | — | ||||||||||||
| Cardiogenesis Cardiac Laser Therapy | — | — | — | — | ||||||||||||
| Other Segments | — | — | — | — | ||||||||||||
| Other Medical Devices | — | — | — | — | ||||||||||||
| Total | $313.79M | $354.00M | $388.54M | $441.33M |
Artivion brought in $441.33M from its five product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 13.6% from $388.54M in fiscal 2024. Aortic Stent Grafts was the largest at $159.37M (36.1%), ahead of On-X at $101.74M (23.1%) and Preservation Services at $95.51M (21.6%). The other two lines brought in $84.71M combined.
Compared with fiscal 2024, Aortic Stent Grafts grew fastest, up 29.5% to $159.37M, while Preservation Services fell the most, down 2.9% to $95.51M. From fiscal 2022 to 2025, combined revenue from these lines grew from $313.79M to $441.33M, a compound annual growth rate of 12.0%. Aortic Stent Grafts' share of the total rose from 29.6% to 36.1%.
North America was Artivion’s largest segment in fiscal 2025, bringing in $221.74M of $441.33M (50%).
| Segment | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $167.54M | $187.60M | $197.94M | $221.74M | ||||||||||||
| Emea | $104.12M | $114.81M | $131.52M | $151.37M | ||||||||||||
| Medical Devices | — | — | — | — | ||||||||||||
| Preservation Services | — | — | — | — | ||||||||||||
| Apac | $27.97M | $33.58M | $37.20M | $44.25M | ||||||||||||
| Latam | $14.16M | $18.01M | $21.88M | $23.97M | ||||||||||||
| Other Segments | — | — | — | — | ||||||||||||
| Other | — | — | — | — | ||||||||||||
| Total | $313.79M | $354.00M | $388.54M | $441.33M |
Artivion brought in $441.33M from its four segments in fiscal 2025, the year ended December 31, 2025. That was up 13.6% from $388.54M in fiscal 2024. North America was the largest at $221.74M (50.2%), ahead of Emea at $151.37M (34.3%) and Apac at $44.25M (10.0%). The remaining segment, Latam, brought in $23.97M.
Compared with fiscal 2024, Apac grew fastest, up 18.9% to $44.25M. Every segment above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these segments grew from $313.79M to $441.33M, a compound annual growth rate of 12.0%. North America's share of the total fell from 53.4% to 50.2%.
Foreign was Artivion’s largest region in fiscal 2025, bringing in $227.26M of $441.33M (51%).
| Geography | FY 2011 | FY 2012 | FY 2013 | FY 2016 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | — | $179.49M | $189.99M | $214.08M | ||||||||
| Domestic | $161.11M | — | — | — | ||||||||
| U.S | — | — | — | — | ||||||||
| Foreign | $152.68M | $174.52M | $198.54M | $227.26M | ||||||||
| International | — | — | — | — | ||||||||
| Total | $313.79M | $354.00M | $388.54M | $441.33M |
Artivion brought in $441.33M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 13.6% from $388.54M in fiscal 2024. Foreign was the largest at $227.26M (51.5%), ahead of United States at $214.08M (48.5%).
Compared with fiscal 2024, Foreign grew 14.5% to $227.26M and United States grew 12.7% to $214.08M.
Artivion began breaking out United States in fiscal 2023, when it brought in $179.49M. Artivion stopped reporting Domestic as a separate region after fiscal 2022, when it brought in $161.11M.
Artivion (AORT) reports its revenue by product and service, by segment and by geography. In fiscal 2025, Aortic Stent Grafts was its largest product and service line, bringing in $159.37M (36.1% of the total), followed by On-X at $101.74M (23.1%).
Aortic Stent Grafts was Artivion's largest product and service line in fiscal 2025, bringing in $159.37M, or 36.1% of the $441.33M total across its five product and service lines.
North America was Artivion's largest segment in fiscal 2025, bringing in $221.74M, or 50.2% of the $441.33M total across its four segments.
Foreign was Artivion's largest region in fiscal 2025, bringing in $227.26M, or 51.5% of the $441.33M total across its two regions.
Among Artivion's product and service lines that make up at least 2% of revenue, Aortic Stent Grafts grew fastest in fiscal 2025, up 29.5% from $123.08M to $159.37M.
Every figure comes from Artivion's annual financial filings, as reported. Each line keeps the name Artivion gives it, and years follow its fiscal calendar.
Artivion's revenue by product and service goes back to fiscal 2010, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.